PharmaFocus Today – Page 72 – media

Study finds AI reduces underdiagnosis of Black patients with common heart failure

A study led by King’s College London (KCL) has revealed that Black patients are less likely to be underdiagnosed with a common type of heart failure when using artificial intelligence (AI), compared to in routine practice. The research, funded by the British Heart Foundation, could help researchers understand the extent of heart failure with preserved ejection fraction (HFpEF) underdiagnosis across ethnicities, as well as reduce bias and improve diagnoses. Heart failure is estimated to affect more than one million people in the UK, 50% of whom have HFpEF, which occurs when the heart pumps out blood normally but cannot fill up as well, leading to signs and symptoms of failure such as breathlessness, fatigue and dizziness. Using an AI algorithm called Natural Language Processing (NLP), which reads and understands medical text and analyses electronic medical records, researchers identified nearly 1,973 patients who met the current European Society of Cardiology guidelines ...
- Source: drugdu
- 103
- August 16, 2024
Cell adhesion and starvation found to be key drivers of pattern formation in keratinocytes

Cell-cell adhesion-induced patterning in keratinocytes can be explained by just starvation and strong adhesion, Hokkaido University researchers find. Fingerprints are one of the best-recognised examples of pattern formation by epithelial cells. The primary cells in the epithelium are the keratinocytes, and they are known to form patterns at the microscopic and macroscopic levels. While factors affecting this pattern formation have been reported, the exact mechanisms underlying the process are still not fully understood. A team of researchers, led by Associate Professor Ken Natsuga at the Faculty of Medicine, Hokkaido University, have revealed that cell-cell adhesion governs pattern formation in keratinocytes. Their findings were published in the journal Life Science Alliance. Ken Natsuga, Associate Professor, Faculty of Medicine, Hokkaido University, said, “In this study, we used an immortalized keratinocyte cell line, called HaCaT, which retains all the properties of normal keratinocytes. In order to ensure that our findings were accurate, we ...
- Source: drugdu
- 79
- August 15, 2024
Humor could be an effective parenting tool, study suggests

They say that laughter is the best medicine, but it could be a good parenting tool too, according to a new study led by researchers from Penn State. In a pilot study, the research team found that most people viewed humor as an effective parenting tool and that a parent or caregiver’s use of humor affected the quality of their relationship with their children. Among those whose parents used humor, the majority viewed their relationship with their parents and the way they were parented in a positive light. The researchers published their findings in the journal PLOS One. Benjamin Levi, professor of pediatrics and humanities at Penn State College of Medicine and senior author of the study, said, “Humor can teach people cognitive flexibility, relieve stress, and promote creative problem solving and resilience. My father used humor and it was very effective. I use humor in my clinical practice and ...
- Source: drugdu
- 131
- August 15, 2024
CMT Research Foundation invests in research project to develop treatments for CMTs

The CMT Research Foundation (CMTRF) has invested in a research project based at Nationwide Children’s Hospital, US, to develop new vehicles for delivering gene therapies to treat several types of Charcot-Marie-Tooth disease (CMT). The new project aims to improve the treatment efficacy and safety of gene therapies for forms of CMTs, including CMT1A, the most prevalent form, which accounts for 50% of all patients with nerve-damaging disorder. Recognised as a rare peripheral neuropathy disease that affects nearly three million people globally, CMT is a group of inherited conditions that damage the peripheral nerves, which are found outside the main central nervous system. The development of safe and effective gene therapies for CMT requires the delivery of a therapeutic genetic payload into the peripheral nervous system, which specifically targets Schwann cells, a type of glial cells that help form the myelin sheath around the nerve fibres, for types of CMT including ...
- Source: drugdu
- 98
- August 15, 2024
Francis Crick scientists reveal how cells ‘raise the alarm’ when damaged or infected

Scientists at the Francis Crick Institute have revealed how cells ‘raise the alarm’ when acids leak out of their compartments if damaged or infected with bacteria or a virus, which could be useful in developing new drugs. The study published in Molecular Cell reveals that one protein known as V1H, which brings in machinery required for autophagy – the degradation of parts of the cell – is involved in this process. Cells in the body need acidic compartments for digestion and recycling nutrients, of which acid is pumped into them by a group of proteins called the V-ATPase or the ‘proton pump’. When the cells are damaged or infected, acid leaks out of these compartments and cells need to be able to detect this. The new study has revealed how cells are able to detect acid leaks and that the V-ATPase complex is able to raise the alarm if the ...
- Source: drugdu
- 88
- August 15, 2024
US judge denies initial attempt by Novartis to block generic Entresto launch

Novartis’s bid to block the launch of a biosimilar for its best-selling drug Entresto (sacubitril/valsartan) got off to a faltering start, as the drugmaker failed to convince a US court that MSN Pharmaceuticals’ (MSNPI) copycat infringed on a patent. Richard Andrews, district judge for the District of Delaware, ruled the likelihood that Novartis would win the lawsuit was not high enough, meaning a preliminary injunction was not granted. While Andrews stated that stopping MSNPI’s generic launch was not justified, he did order a temporary 72-hour halt while Novartis goes to the US Court of Appeal to seek an injunction, as per a 12 August court document first released by Reuters. The hearing is part of a lawsuit initiated by Novartis to fend off MSNPI’s generic – which received US Food and Drug Administration (FDA) approval last month – to protect sales for its heart failure blockbuster. Novartis’s reference drug was ...
- Source: drugdu
- 79
- August 15, 2024
Hengrui’s Dexmedetomidine Hydrochloride Injection Passed GMP Certification Inspection in Japan

Recently, Hengrui Pharmaceuticals has received the GMP certificate issued by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for its preparation production site located at No. 38, Huanghe Road, Lianyungang, and the company’s Dexmedetomidine Hydrochloride Injection has successfully passed the GMP compliance inspection by PMDA. This is the company’s quality management system again recognized by international authoritative institutions after the API dexmedetomidine hydrochloride PMDA site inspection was passed, which is conducive to the company to further strengthen the internationalization strategy and enhance the competitiveness in the global market. Japanese GMP certification is one of the authoritative certifications in the field of international drug production, and the inspection is characterized by rigor, meticulousness and attention to details.2023 In September, two qualification inspectors of Japan PMDA conducted a GMP on-site inspection for several days on Hengrui Pharmaceuticals’ Dexmedetomidine Hydrochloride Injection production line at the preparation production site located at No. 38 Huanghe Road, ...
- Source: drugdu
- 79
- August 15, 2024
Study suggests COVID-19 vaccination lowers incidence of arterial thromboses

Researchers from the Universities of Cambridge, Bristol and Edinburgh have suggested that COVID-19 vaccinations could lower the incidence of arterial thromboses. The study, published in Nature Communications, was supported by the British Heart Foundation (BHF) Data Science Centre at Health Data Research UK. Researchers analysed the de-identified health records of 46 million adults from GP practices, hospital admissions and death records in England between December 2020 and January 2022, provided by NHS England. The team compared the incidence of cardiovascular diseases (CVDs) following COVID-19 vaccination with the incidence before or without vaccination during the first two years of the vaccination programme. CVD affects around seven million people in the UK and is a significant cause of disability and death. Overall, the study revealed that the incidence of arterial thromboses, such as heart attacks and strokes, which affect 200,000 people in the UK every year combined, was up to 10% lower ...
- Source: drugdu
- 67
- August 14, 2024
UCL study reveals routine blood tests could improve early cancer diagnosis

Researchers from University College London (UCL) have found that common routine blood tests could be used to speed up and improve early cancer diagnosis for patients in a new study published in PLOS Medicine. Researchers analysed data from more than 400,000 people aged 30 or older in the UK who had visited a GP due to stomach pain from the Clinical Practice Research Datalink, collected between 2007 and 2016, and from more than 50,000 who had visited their GP due to bloating – two-thirds of whom had blood tests following their appointment. The team found abnormal results in 19 commonly used blood tests were linked to a higher risk of being diagnosed with cancer within a year – one in 50 people who reported stomach pain, as well as bloating, to a GP were diagnosed with cancer within 12 months. If taken into account, researchers estimated that there would have ...
- Source: drugdu
- 80
- August 14, 2024
Pfizer touts positive topline data for RSV vaccine Abrysvo

Pfizer has announced positive topline results from a pivotal late-stage study of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults who are immunocompromised and at risk of developing severe RSV-associated lower respiratory tract disease (LRTD). As per the 12 August press release, Abrysvo was found to be well tolerated in the substudy B portion of the pivotal Phase III MONeT study (NCT05842967). While substudy B evaluated two 120 µg dose doses of Abrysvo, Pfizer reported that a single 120 µg dose of the vaccine led to “strong neutralizing” responses against RSV-A and RSV-B. The safety profile of Abrysvo was consistent with that of previous studies. “Immunocompromised adults, such as patients with cancer or autoimmune disorders, have a substantially increased risk of experiencing severe complications from RSV, yet there are currently no vaccines approved for those aged 18 to 59 in the U.S.,” said senior vice president and CSO, Vaccine ...
- Source: drugdu
- 80
- August 14, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.